Geographical distribution and prevalence of podoconiosis in Rwanda: a cross-sectional country-wide survey by Deribe, Kebede et al.
www.thelancet.com/lancetgh   Published online March 26, 2019   http://dx.doi.org/10.1016/S2214-109X(19)30072-5 1
Articles
Lancet Glob Health 2019 
Published Online 
March 26, 2019 
http://dx.doi.org/10.1016/
S2214-109X(19)30072-5
See Online/Comment 
http://dx.doi.org/10.1016/
S2214-109X(19)30158-5
Wellcome Trust Brighton and 
Sussex Centre for Global Health 
Research, Brighton and Sussex 
Medical School, Brighton, UK 
(K Deribe PhD, M J Newport PhD, 
G Davey MD); School of Public 
Health, Addis Ababa University, 
Addis Ababa, Ethiopia (K Deribe, 
F Enquselassie PhD, G Davey); 
Malaria and Other Parasitic 
Disease Division, Rwanda 
Biomedical Center–Ministry of 
Health, Kigali, Rwanda 
(A Mbituyumuremyi MD, 
M Jean Bosco BSc, 
E Ruberanziza MD, 
U Bayisenge MD, J U Condo PhD); 
Department of Disease Control, 
London School of Hygiene & 
Tropical Medicine, London, UK 
(J Cano PhD, E Giorgi PhD, 
R L Pullan PhD); Lancaster 
Medical School, Faculty of 
Health and Medicine, Lancaster 
University, Lancaster, UK 
(E Giorgi); Byumba Hospital, 
Kibali, Rwanda (U Leonard BSc); 
Heart and Sole Africa in 
Ruhengeri, Musanze, Rwanda 
(J P Bikorimana MSc); National 
Reference Laboratory 
(A Rucogoza MSc) and Institute 
of HIV/AIDS, Disease Control 
and Prevention Department 
(I Turate MD), Rwanda 
Biomedical Center, Kigali, 
Rwanda; World Health 
Organization, Rwanda Country 
Office, Kigali, Rwanda 
(A Rusanganwa MD); Institute 
for Health Metrics and 
Evaluation, University of 
Washington, Seattle, WA, USA 
(D M Pigott DPhil, 
C J L Murray DPhil, 
S I Hay FMedSci); Kenya Medical 
Research Institute–Wellcome 
Trust Collaborative 
Programme, Nairobi, Kenya 
(A M Noor PhD); Centre for 
Tropical Medicine and Global 
Geographical distribution and prevalence of podoconiosis in 
Rwanda: a cross-sectional country-wide survey
Kebede Deribe, Aimable Mbituyumuremyi, Jorge Cano, Mbonigaba Jean Bosco, Emanuele Giorgi, Eugene Ruberanziza, Ursin Bayisenge, 
Uwayezu Leonard, Jean Paul Bikorimana, Aniceth Rucogoza, Innocent Turate, Andre Rusanganwa, David M Pigott, Rachel L Pullan, 
Abdisalan M Noor, Fikre Enquselassie, Jeanine U Condo, Christopher J L Murray, Simon J Brooker, Simon I Hay, Melanie J Newport, Gail Davey
Summary
Background Podoconiosis is a type of tropical lymphoedema that causes massive swelling of the lower limbs. The 
disease is associated with both economic insecurity, due to long-term morbidity-related loss of productivity, and intense 
social stigma. Reliable and detailed data on the prevalence and distribution of podoconiosis are scarce. We aimed to fill 
this data gap by doing a nationwide community-based study to estimate the number of cases throughout Rwanda.
Methods We did a population-based cross-sectional survey to determine the national prevalence of podoconiosis. 
A podoconiosis case was defined as a person with bilateral, asymmetrical lymphoedema of the lower limb present for 
more than 1 year, who tested negative for Wuchereria bancrofti antigen (determined by Filariasis Test Strip) and specific 
IgG4 (determined by Wb123 test), and had a history of any of the associated clinical signs and symptoms. All adults 
(aged ≥15 years) who resided in any of the 30 districts of Rwanda for 10 or more years were invited at the household 
level to participate. Participants were interviewed and given a physical examination before Filariasis Test Strip and 
Wb123 testing. We fitted a binomial mixed model combining the site-level podoconiosis prevalence with continuous 
environmental covariates to estimate prevalence at unsampled locations. We report estimates of cases by district 
combining our mean predicted prevalence and a contemporary gridded map of estimated population density.
Findings Between June 12, and July 28, 2017, 1 360 612 individuals—719 730 (53%) women and 640 882 (47%) men—
were screened from 80 clusters in 30 districts across Rwanda. 1143 individuals with lymphoedema were identified, of 
whom 914 (80%) had confirmed podoconiosis, based on the standardised diagnostic algorithm. The overall prevalence 
of podoconiosis was 68·5 per 100 000 people (95% CI 41·0–109·7). Podoconiosis was found to be widespread in 
Rwanda. District-level prevalence ranged from 28·3 per 100 000 people (16·8–45·5, Nyarugenge, Kigali province) to 
119·2 per 100 000 people (59·9–216·2, Nyamasheke, West province). Prevalence was highest in districts in the North 
and West provinces: Nyamasheke, Rusizi, Musanze, Nyabihu, Nyaruguru, Burera, and Rubavu. We estimate that 
6429 (95% CI 3938–10 088) people live with podoconiosis across Rwanda.
Interpretation Despite relatively low prevalence, podoconiosis is widely distributed geographically throughout 
Rwanda. Many patients are likely to be undiagnosed and morbidity management is scarce. Targeted interventions 
through a well coordinated health system response are needed to manage those affected. Our findings should inform 
national level planning, monitoring, and implementation of interventions.
Funding Wellcome Trust.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Podoconiosis is a type of tropical lymphoedema that 
is caused by long-term exposure to volcanic soils.1 The 
disease occurs among genetically susceptible individuals 
who do not use proper footwear.2,3 The disease is thought 
to be endemic in 32, mostly tropical, countries4 and it 
is estimated that 4 million people globally are currently 
living with podoconiosis.3 Owing to its high burden of 
morbidity, those with podoconiosis suffer severe stig-
matisation,5,6 reduced quality of life7 and productivity,8 
and increased rates of depression.9
Limited and inequitable access to morbidity manage-
ment services for neglected tropical diseases is a cause of 
growing concern globally.10 Podoconiosis is a neglected 
tropical disease and is common in low-income and 
middle-income countries.4 In these countries, inadequate 
surveillance systems, dysfunctional community referral 
systems, and poor awareness are the most common 
barriers to the provision of podoconiosis care. The 
overall burden of podoconiosis is largely unknown, even 
within endemic countries, severely limiting advocacy for 
intervention and evaluation at the national level.11
Reliable and detailed data on the prevalence and 
distribution of podoconiosis globally are scarce; those 
available are restricted to scattered endemic communities 
and case reports,4 leaving the actual prevalence within 
confirmed and suspected endemic areas unknown.11 To 
date, available estimates of podoconiosis largely depend on 
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expert opinion. These estimates have been useful in 
raising necessary awareness, yet are clearly insufficient 
for planning national control programmes. A 2018 sys-
tematic review4 found an absence of prevalence data on 
podoco niosis in many of the suspected endemic countries.4
Over the past decade, the global health community 
has recognised the need to accurately estimate podoco-
niosis burden within endemic countries.11 In Rwanda, 
only one study,1 done in 1976, has documented the 
prevalence of visible lymphoedema in a market-based 
analysis. This work estimated a prevalence of 0·63% of 
visible lymphoedema across Rwanda. Although this 
study is a landmark paper in podoconiosis research, it 
has two notable limitations. First, it was based on the 
observation of visible lymphoedema and did not 
exclude other potential causes of lymphoedema.1 
Second, the study’s target population included only 
those who attended markets, leaving out the possibility 
of additional cases. No additional research has been 
done to estimate the prevalence of podoconiosis in 
Rwanda. Updated and robust estimates of the 
distribution and number of cases of podoconiosis in 
Rwanda will help to identify endemic areas that require 
intervention and exclude areas without risk of the 
disease. It is also important to define the number of 
people with podoconiosis in the country, to enable 
effective planning and careful use of resources.
This study is part of a larger initiative to develop the 
global atlas of podoconiosis.11 We aimed to determine the 
prevalence and geographical distribution of podoconiosis 
within all districts of Rwanda among the adult population 
(aged ≥15 years) and to estimate the number of podo-
coniosis cases by district across the country. We did a 
nationwide survey and used the observed prevalence at 
selected sites to construct a predictive prevalence model 
for the entire country. In presenting the results, we 
address the essential first step of the WHO action plan 
of elimination of neglected tropical diseases: mapping 
the geographical distribution of such diseases.12
Research in context
Evidence before this study
We searched PubMed, Embase, and Popline databases for 
original studies of prevalence of podoconiosis in Rwanda 
published between Jan 1, 1970, and Aug 9, 2018, with no 
language restrictions. We used the search terms “podoconiosis” 
AND “non-filarial elephantiasis” AND “prevalence”, AND 
“Rwanda”, and manually searched the reference lists of articles 
identified. One study on the prevalence of elephantiasis in 
Rwanda was published in 1976. The study observed cases in 
special clinics and market-based surveys, and identified 
133 elephantiasis cases in special clinics. 20 446 individuals were 
screened in 14 markets, giving a prevalence of 6·26 per 1000 
(range 1·2–16·7 per 1000 per market). To our knowledge, no 
community-based study has been done to estimate the 
prevalence of podoconiosis in Rwanda.
Added value of this study
This study is the first community-based study to estimate the 
prevalence of podoconiosis in Rwanda, and is also the first 
study in Rwanda to use a clinical algorithm to diagnose 
podoconiosis by excluding other potential causes of 
lymphoedema. We excluded Wuchereria bancrofti antigen and 
specific IgG4 using the Filariasis Test Strip and Wb123 tests, 
respectively. We fitted a binomial mixed model combining the 
site-level podoconiosis prevalence with continuous 
environmental covariates to estimate prevalence at unsampled 
locations. Finally, we produced estimates of cases by district, 
combining our mean predicted prevalence and a contemporary 
gridded map of estimated population density.
Implications of all the available evidence
Despite the relatively low prevalence, our findings show that 
podoconiosis is widely distributed throughout Rwanda. 
Estimating the number of cases and the geographic distribution 
of podoconiosis is important for local advocacy, policy, 
and programming of podoconiosis interventions in Rwanda. 
The methods we used are likely to inform mapping of the 
global distribution of podoconiosis.
Figure 1: Distribution of surveyed communities and prevalence of podoconiosis across Rwanda
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Methods
Study design and participants
We did a population-based cross-sectional survey on 
podoconiosis targeting all 30 districts in Rwanda. In 
July, 2017, trained community health workers did a census 
of the communities within the selected sectors (a sector 
being the smallest administrative unit in Rwanda). In 
November, 2017, expert clinical diagnostic teams verified 
all suspected cases of lymphoedema (listed by community 
health workers) within these sectors. Rwanda is a densely 
populated, landlocked country of about 26 000 km² in 
central eastern Africa. The country has a population of 
12·1 million people (as of 2018)13 and is administratively 
divided into five provinces, 30 districts, and 416 sectors.13 
Important country indicators include maternal mortality 
of 210 per 100 000 livebirths and child mortality of 
50 per 1000 livebirths.14 The average life expectancy is 
66·6 years.13
All adults (aged ≥15 years) who lived in any of the 
30 districts were included in the study. Exclusion criteria 
were terminally ill patients who could not respond 
to the interview and patients with a mental health 
condition that would make interviewing difficult and 
results unreliable.
Ethical approval was obtained from the Rwanda 
National Ethics Committee and the Brighton and Sussex 
Medical School Research Governance and Ethics 
Committee, Brighton, UK. Written informed consent 
was obtained from all respondents, except for illiterate 
respondents who provided their thumbprint and a 
signature from a literate witness. Individuals younger 
than 18 years provided assent and a parent or guardian 
provided written consent.
A summary of the protocol is available in the appendix.
Procedures
Between June 12, and July 28, 2017, 282 trained commu-
nity health workers did a census of the communities 
within the selected sectors. They registered residence, sex, 
and age, and recorded the presence of leg swelling of 
any type. All individuals with swelling of one or both 
lower limbs were documented as suspected cases during 
an exhaustive house-to-house census and case listing. 
Community volunteers were provided with case defin-
itions and pictures of podoconiosis-related morbidity to 
identify the suspected cases.
Between Nov 19, and Dec 6, 2017, expert clinical 
diagnostic teams verified all suspected cases of 
lymphoedema (listed by community health workers) 
within the randomly selected sectors, on the basis of 
procedures previously used in Cameroon.15 Each team 
included four health workers, a medical doctor, a 
nurse, a laboratory technician, and a team leader. To 
ensure effective community engagement, members of 
the team were recruited from the targeted sectors. 
Ques tionnaires were translated into Kinyarwanda 
language and data were collected using the LINKS 
software package (version 1.4.2; Secure Data Kit, 
Atlanta, GA, USA) installed onto Android smart-
phones.16 Individual data on age, sex, education, 
occupation, place of resi dence, shoe wearing, and foot 
hygiene practices were recorded, as were household 
data on water, sani tation, and hygiene. Geographic 
coordinates from sur veyed communities were taken 
using smartphones. Data collectors could not proceed 
to the next question without completing all required 
fields. We used automated skip patterns to maintain the 
quality of the data.
Each patient with suspected podoconiosis underwent 
a complete physical examination in a private room at 
the nearest public health centre. We used data collection 
methods used in previous similar surveys done in other 
countries.15,17 Key questions were age at onset of swelling, 
family member (living or dead) with history of leg 
swelling, type of swelling (ascending or descending), 
and self-reported chronic illness, such as heart disease, 
kidney disease, or diabetes. Ascending swelling refers 
to swelling that starts from the foot and progresses up 
the leg; descending swelling is swelling that starts 
from the upper leg or groin area and progresses down. 
Suspected patients were also asked about previous 
clinical diagnoses of known causes of lymphoedema 
(such as congenital disorders, leprosy, and postoperative 
lymphoedema) and about the co-occurrence of swelling 
in other parts of the body, such as the hands, face, and 
scrotum (hydrocele).
Differential diagnosis with lymphatic filariasis
All lymphoedema cases were screened for circulating 
Wuchereria bancrofti antigen, using Filariasis Test Strips, 
and circulating specific IgG4 antibody, using Wb123 tests. 
Screening was done by trained laboratory technicians 
Figure 2: Study profile
Podoconiosis was diagnosed via history, physical examination, and disease-specific 
tests. 
1143 patients with lymphoedema 
were screened 
9 excluded
6 Filariasis Test Strip-positive
3 Wb123-positive
1134 tested negative for FTS and 
Wb123 
220 excluded
61 loss of sensation
53 swelling on other parts of 
the body
29 descending swelling
28 signs and symptoms of 
other diseases
19 lymphoedema after major 
surgical procedure
14 swelling started at age 
<5 years
9 swelling at birth
7 diagnosed with leprosy
 914 diagnosed with podoconiosis 
See Online for appendix
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according to the manufacturer’s instructions.18,19 Test 
results with the individual’s unique ID number were 
recorded both on the card, and on each individual’s data 
questionnaire.
Briefly, for the rapid test, we used positive and 
negative controls for quality control of test batches 
before starting the daily activity. The patient’s third 
or fourth finger was cleaned with 70% alcohol and 
punctured using a sterile lancet. The initial drop of blood 
was removed using a cotton swab, and sufficient fresh 
blood was obtained to fill a 75-μl capillary tube. The blood 
sampled was transferred from the capillary tube to the 
pad on a Filariasis Test Strip card. The result of each card 
was read at 10 min exactly. A positive result was two lines, 
and a negative result was a single line. The tests were 
repeated if the control line was not shown.
For the detection of IgG4 antibodies against W bancrofti, 
10-μl capillary blood was transferred from the capillary 
tube to the pad of a Wb123 card and four drops of assay 
diluent were dispensed vertically into the square assay 
Non-podoconiosis 
(n=229)
Podoconiosis 
(n=914)
Age, years
15–24 15 (7%) 56 (6%)
25–34 17 (7%) 88 (10%)
35–44 32 (14%) 151 (17%)
45–54 40 (17%) 184 (20%)
55–64 54 (24%) 180 (20%)
65–74 41 (18%) 136 (15%)
75–84 21 (9%) 95 (10%)
≥85 9 (4%) 24 (3%)
Median age, years 55 (43–68) 53 (40–66)
Employment
Subsistence 214 (93%) 800 (88%)
Not working 9 (4%) 100 (11%)
Self-employed 3 (1%) 6 (1%)
Salaried 3 (1%) 6 (1%)
Housework 0 2 (<1%)
Sex
Male 83 (36%) 276 (30%)
Female 146 (64%) 638 (70%)
Educational achievements
No formal education 155 (68%) 642 (70%)
Primary 70 (31%) 249 (27%)
Secondary 1 (<1%) 19 (2%)
Tertiary 3 (1%) 4 (<1%)
Marital status
Single 30 (13%) 155 (17%)
Married 114 (50%) 432 (47%)
Divorced 19 (8%) 70 (8%)
Widowed 66 (29%) 257 (28%)
Type of floor in the household
Earth or sand 209 (92%) 837 (92%)
Ceramic tiles 20 (9%) 64 (7%)
Dung 0 9 (1%)
Carpet 0 3 (<1%)
Vinyl or asphalt strips 0 1 (<1%)
Have you ever worn shoes?
Yes 218 (95%) 858 (94%)
No 11 (5%) 56 (6%)
Median age at wearing shoes, 
years (IQR)
23 (12–30) 24 (13–30)
Wearing shoes during the interview?
Yes 194 (85%) 770 (84%)
No 35 (15%) 88 (16%)
(Table 1 continues in next column)
Non-podoconiosis 
(n=229)
Podoconiosis 
(n=914)
(Continued from previous column)
Type of shoe worn during the interview
Hard plastic 99 (43%) 380 (42%)
Open sandal 69 (30%) 291 (32%)
Leather 18 (8%) 66 (7%)
Canvas 6 (3%) 27 (3%)
Other 2 (1%) 6 (1%)
Family history of leg swelling
Yes 91 (40%) 390 (43%)
No 138 (60%) 524 (57%)
Age at onset of swelling, years 25 (15–39) 21 (15–36)
Source of water
Pipe-borne 186 (81%) 633 (70%)
Borehole or well 14 (6%) 128 (14%)
River or stream 20 (9%) 120 (13%)
Pond or stagnant 9 (4%) 33 (4%)
Location of water source
Elsewhere 222 (97%) 873 (96%)
In own yard or plot 0 14 (2%)
In own dwelling 7 (3%) 27 (3%)
Time taken to go to water 
source, collect water, and 
return home, mins
30 (20–60) 30 (20–60)
Podoconiosis disease stage*
Stage 1 ·· 274 (30%)
Stage 2 ·· 443 (48%)
Stage 3 ·· 169 (18%)
Stage 4 ·· 23 (3%)
Stage 5 ·· 5 (1%)
Have you experienced an acute attack in the past 6 months?
Yes ·· 512 (56%)
No ·· 402 (44%)
Data are n (%) or median (IQR). *Stage 1, swelling reversible overnight. Stage 2, 
below-knee swelling that is not completely reversible overnight; if present, knobs 
or bumps are below the ankle only. Stage 3, below-knee swelling that is not 
completely reversible overnight; knobs or bumps are above the ankle. Stage 4, 
above-knee swelling that is not completely reversible overnight; knobs or bumps 
are at any location. Stage 5, swelling at any place in the foot or leg; the ankle or 
toe joints become fixed and difficult to flex or dorsiflex; these symptoms can be 
accompanied by apparent shortening of the toes.
Table 1: Baseline characteristics
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diluent well. The result of each Wb123 card was read at 
30 min. A positive result was two lines, and a negative 
result was a single line.
Modelling of podoconiosis prevalence
The following covariates were used in our analysis in 
a gridded format (raster datasets): precipitation, day 
land surface temperature, elevation, enhanced vegetation 
index, distance from closest waterway, clay content, silt 
content, night light emissivity, and distance to stable 
night light (appendix). These factors are associated with 
podoconiosis and have been included in previous mod-
elling studies.20 Details on the source and processing are 
available in the appendix.
Input grids were resampled to a common spatial 
resolution of 1 km² using the nearest neighbour ap-
proach and clipped to match the geographic extent of a 
map of Rwanda, and eventually aligned to the map. 
Raster manipulation and processing was done using the 
raster package in R v3.3.2 and final map layouts created 
with ArcGIS software (version 10.5; Esri, Redlands, CA, 
USA). Geographic coordinates of each community were 
used to extract estimates from the aforementioned 
covariates.
Outcomes
We defined a podoconiosis case as a person residing in 
the surveyed district for at least 10 years who had bilateral, 
asymmetrical lymphoedema of the lower limb lasting 
for more than 1 year, negative Filariasis Test Strip (Alere; 
Scarborough, ME, USA) and Wb123 tests, and a history 
of any of the signs and symptoms associated with 
podoconiosis.17 We collected occu pational data in pre-
coded categories: government employee, non-government 
em ployee, subsistence far mer or fishing, self-employed, 
full-time student, at home doing house work, unemployed 
(but able to work), unemployed (unable to work), and 
retired. Collected data were screened every day by the 
field supervisors and immediate feedback was given to 
the enumerators; field team leaders gave overall feedback 
and supervision. Final assessment of the full database 
was done after data collection every day to identify 
inconsistencies and missing items.
We used a system for grading the clinical stages of 
podoconiosis that had been developed and validated in 
Ethiopia previously.21 The system has five stages: stage 1, 
swelling reversible overnight (ie, the swelling is not 
present when the patient first gets up in the morning); 
stage 2, below-knee swelling that is not completely 
reversible overnight, with knobs or bumps below the 
ankle only (if present); stage 3, below-knee swelling that 
is not completely reversible overnight, with knobs or 
bumps above the ankle; stage 4, above-knee swelling 
that is not completely reversible overnight, with knobs 
or bumps at any location; and stage 5, swelling at any 
place in the foot or leg, and the ankle or toe joints 
become fixed and difficult to flex or dorsiflex—these 
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Burundi
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DR Congo
Burundi
Tanzania
Uganda
B
0 25 50 km
Estimated number of people with
podoconiosis
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Figure 3: Predicted prevalence of podoconiosis
Mean predicted prevalence of podoconiosis (A) and estimated number of people with podoconiosis (B).
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symptoms can be accompanied by apparent shortening 
of the toes.
Statistical analysis
The survey used a cluster sampling design. We included 
all 30 districts of Rwanda. In each district, at least 
two sectors were randomly selected. The survey was 
powered to generate prevalence estimates for podoco-
niosis with a precision of 0·003% at the national level, 
assuming a conservative prevalence estimate of 42 cases 
per 100 000 from a surveillance report (M Jean Bosco, 
Rwanda Biomedical Center–Ministry of Health, per-
sonal communication). Under a design effect of 1·6 
(calculated from a mapping survey in Cameroon)15 and a 
community participation rate of 80%, we estimated a 
sample size of 986 376 individuals to be screened from 
60 sectors (two sectors per district). To adjust for sector 
size, sectors were assigned to districts proportional to 
the number of sectors per district. The adjustment 
resulted in 80 of 416 sectors being selected, with 
independent selection in each district. In the selected 
sectors, a census of all eligible individuals was done. All 
individuals aged 15 years and older, who had lived in the 
area for at least 10 years before the survey (to exclude 
individuals who might have acquired lymphoedema 
elsewhere) were included.
We described the individual characteristics and 
prevalence of lymphoedema and podoconiosis with 
95% CIs. We estimated district-level prevalence and 
number of cases across Rwanda using a binomial mixed 
model, accounting for fixed effects (covariates) and 
random effects. We chose this method over geostatistical 
and Bayesian frameworks on the basis of the absence of 
spatial structure on podoconiosis prevalence, explored 
by fitting an empirical variogram (appendix). Spatial 
dependence is a prerequisite for such methods. Our 
model used the prevalence estimates and covariates 
for smoothing the prediction. Briefly, let Yi denote the 
random variable associated with the number of positively 
detected cases of podoconiosis at a community location xi. 
We then modelled Yi using a binomial mixed model with 
probability of having podoconiosis p(xi) such that:
where the dj(xi) are georeferenced covariates and Zi are 
independent and identically distributed zero-mean 
Gaussian variables with variance σ². We fitted the model 
using the lme4 package (version 3.4) in R software.22 Using 
the approach described by Bates and colleagues,23 we tested 
the presence of residual spatial correlation by generating 
the 95% CIs for the variogram of the random effects Zi 
under the assumption of spatial independence. As the 
variogram that was based on the estimated Zi using the 
original data fell within the 95% CIs, we concluded that 
Figure 4: District-level predicted prevalence of podoconiosis
Mean predicated prevalence of podoconiosis (A) and estimated number of people with podoconiosis (B).
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there was no evidence of residual spatial correlation. 
Therefore, a bi nomial non-spatially explicit mixed model 
was constructed. This model was used to produce 
continuous predictions of podoconiosis prev alence at 
1 km² spatial resolutions. We also developed a probability 
map of exceeding 0·1% prevalence. For a given location x, 
we obtain
where βj hat is the maximum likelihood estimate of the 
regression coefficient βj for j=0,1,...,9. To compute the 
probability of exceeding 0·1% prevalence, we used the 
multivariate Gaussian approximation of the maximum 
likelihood estimator.24
Gridded maps of population density and age structure 
were obtained from the WorldPop project.25,26 We used 
this gridded population surface to compute the estimates 
of affected population by pixel, by multiplying prevalence 
of podoconiosis in 1 km² area with the corresponding 
population at the same spatial resolution. We used this 
surface to extract the aggregate number of people with 
podoconiosis by district.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author and the last author 
had full access to all the data and had final responsibility 
for the decision to submit for publication.
Results
Between June 12, and July 28, 2017, 1 360 612 indi-
viduals—640 882 (47%) men and 719 730 (53%) women—
were screened by community health workers in 
80 sectors in 30 districts (figure 1). 1143 individuals with 
lymphoedema were identified and tested using Filariasis 
Test Strip and Wb123 tests. 229 (20%) of 1143 were 
excluded for having non-podoconiosis lymphoedema 
(figure 2).
914 (80%) individuals with swelling of lower limbs were 
considered to be podoconiosis cases, yielding a prevalence 
of 68·5 per 100 000 people (95% CI 41·0–109·7). The 
median age was 55 years (IQR 43–68) for people with non-
podoconiosis lymphoedema and 53 years (40–66) for 
people with podoconiosis (table 1). 214 (93%) people with 
non-podoconiosis lymphoedema and 800 (88%) people 
with podoconiosis reported subsistence farming as 
their occupation. Most participants reported no formal 
education and most participants with lymphoedema lived 
in a household with an earth or sand floor, although the 
majority were wearing shoes during the interview (table 1).
The predicted distribution of podoconiosis risk was het-
erogeneous, varying from 3·3 to 307 per 100 000 (figure 3). 
The highest prevalence is predicted in restricted areas 
in the north and southwest, which are also the least 
populated areas in Rwanda. 17 clusters with prevalence 
exceeding 1 per 1000 were recorded in 11 districts, 
mostly in northern and western provinces. The predicted 
prevalence of podoconiosis was highest in the North 
and West provinces, where prevalence exceeded more 
than 70 per 100 000 in most districts. The districts with the 
highest prevalence were Nyamasheke (119·3 per 100 000) 
and Rusizi (117·0 per 100 000) in the West province, 
followed by Musanze Nyabihu, Nyaruguru, Burera, and 
Rubavu.
The highest number of people with podoconiosis was 
predicted in the West province (2096, 95% CI 1140–3591). 
In the eastern and northern districts, the prevalence and 
number of cases is low (figure 4). Nationally, we estimated 
0·1% 
1 – 0·1%
Prob {β0+∑    ˆ 9
j=1
βˆ jd j(x)>log }( ) (2)
Podoconiosis cases, n 95% CI
East
Bugesera 187 129–262
Gatsibo 237 161–337
Kayonza 175 120–246
Kirehe 196 126–291
Ngoma 194 131–277
Nyagatare 267 183–380
Rwamagana 150 105–208
Kigali
Gasabo 91 52–164
Kicukiro 54 29–100
Nyarugenge 22 10–48
North
Burera 313 193–487
Gakenke 262 161–405
Gicumbi 290 176–452
Musanze 317 187–512
Rulindo 193 127–281
South
Gisagara 170 115–242
Huye 150 100–218
Kamonyi 160 115–218
Muhanga 127 77–199
Nyamagabe 215 127–343
Nyanza 157 108–221
Nyaruguru 231 141–362
Ruhango 175 124–241
West
Karongi 241 149–373
Ngororero 245 148–387
Nyabihu 246 123–445
Nyamasheke 449 232–798
Rubavu 291 165–479
Rusizi 381 178–725
Rutsiro 243 146–384
National total 6429 3938–10 088
Table 2: Estimated number of podoconiosis cases by province and district
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that 6429 people (95% CI 3938–10 088) were living with 
podoconiosis (table 2). 27 of 30 districts had at least 
100 predicted podoconiosis cases and 15 had more than 
200 predicted podoconiosis cases (table 2). Maps 
displaying the uncertainties around the predicted prev-
alence and estimates of number of cases are included 
in the appendix. We also estimated the continuous 
probability of exceeding 1 case per 1000 across the 
endemic areas (figure 5). Most of the country had a low 
probability of exceeding this prevalence, and only a few 
districts in the north and southwest of the country would 
potentially exceed that threshold.
Discussion
This study is, to our knowledge, the first nationwide, 
population-based study of podoconiosis in Rwanda. 
Our findings suggest that although the prevalence of 
podoconiosis is low (68·5 estimated cases per 100 000), it 
is widespread through out Rwanda, indicating that 
environmental conditions suitable for the occurrence 
of podoconiosis are present throughout most of the 
country. According to our fitted model, 6429 individuals 
potentially have podoconiosis in Rwanda. We found 
considerable geographical variability in the prevalence of 
podoconiosis across the country. The highest prevalence 
foci for podoconiosis are predicted in the north and 
southwest districts, although cases are widely distributed 
across all 30 districts of Rwanda. The number of cases 
highlights the need to address this issue through a health 
system response.
The prevalence of podoconiosis in this study is lower 
than the findings reported in other endemic countries in 
Africa.4 For example, estimated prevalence is 2·73–7·45% 
in Ethiopia, in Cameroon 0·51–8·08%, and in Uganda 
0·10–4·52%.4 The lower prevalence of podoconiosis in our 
study than in other studies done in the aforementioned 
countries might result from differences in survey design, 
case definition, or areas targeted for the survey (most 
studies were done in endemic areas4), amongst other 
things. However, another plausible reason might be 
a greater use of prevention measures, such as footwear 
and improved access to water in Rwanda. Over the last 
two decades, Rwanda has registered impressive economic 
development.27,28 Prevalence of podoconiosis was highest 
in districts in the north and southwest of the country. 
Districts in the Kigali province had the lowest prevalence 
of podoconiosis, despite being highly populated. Kigali 
is one of the most developed and socioeconomically 
advanced provinces in the country; thus lower prevalence 
of podoconiosis is to be expected. This finding suggests 
that the Ministry of Health in Rwanda should consider 
district-specific interventions, by prioritising districts with 
higher numbers of cases.
Previous reports29 have highlighted the absence of 
lymphatic filariasis in Rwanda, but the causes of lymph-
oedema in the country had not been comprehensively 
studied until now. Our study indicates that 80% of tropical 
lymphoedema in Rwanda is due to podoconiosis; this 
value is high compared with the proportion reported 
in Cameroon (63%)15 and Ethiopia (65%).30 This disparity 
implies that front-line health workers in Rwanda should 
be given podoconiosis training to increase the index of 
suspicion for podoconiosis when people present with 
lymphoedema. Morbidity management services inte-
grated with regular health services should be implemented. 
Loss of sensation was one of the most frequent clinical 
features used to exclude podoconiosis. Podoconiosis 
patients have intact nerves and no loss of sensation in their 
legs is expected from this condition.17 The cause of loss of 
sensation in our study could be diabetic neuropathy, which 
is common among patients with diabetes in Rwanda.31 
However, we cannot exclude undiagnosed leprosy.32
Six (0·5%) Filariasis Test Strip tests and three (0·3%) 
Wb123 tests were positive among the screened lymph-
oedema cases. None of these individuals was positive for 
both tests. The six Filariasis Test Strip-positive patients 
were from five districts: Ngoma in East province, Gasbo in 
Kigali province, Gisagara and Nyamagabe in South 
province, and Rusizi in West province. These findings are 
not the first time that antigen-positive cases have been 
reported in Rwanda. In a 2008 survey, of 797 individuals 
surveyed, a single immunochromatographic card test-
positive case was found and, through subsequent tests, the 
person was confirmed to harbour W bancrofti. However, 
subsequent screening of 200 individuals from the same 
Figure 5: Probability of podoconiosis prevalence exceeding 1 per 1000 people in Rwanda
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Probability of podoconiosis prevalence
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0·1–0·19
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district found no positive cases, confirming the absence 
of ongoing transmission of lymphatic filariasis in the 
district.29 In another survey done in 13 districts in 2008, 
two immunochromatographic card test-positive cases 
were found among 1494 individuals surveyed in 
two districts.33 In our study, we tested indi viduals with 
lymphoedema, which increased the odds of identifying 
lymphatic filariasis-related cases compared with surveying 
the general population. Given these findings and the 
specificity34 of the tests, our results do not suggest ongoing 
transmission of lymphatic filariasis in Rwanda. To confirm 
the results of the Filariasis Test Strip-positive cases, we are 
working with the national programme to test these 
individuals using thick blood smear done at night.
Our findings suggest that podoconiosis is a widespread 
problem in Rwanda and is present in all 30 districts. 
Prevalence varied from 28·3 per 100 000 (95% CI 
16·8–45·5; Nyarugenge, Kigali province) to 119·2 per 
100 000 (59·9–216·2; Nyamasheke, West province) be-
tween districts, and was highest in districts in the North 
and West provinces. The geography of the two highest 
prevalence provinces is favourable for the occurrence of 
podoconiosis, given that mountains dominate in the 
western part of Rwanda, and volcanic chains in the north. 
The eastern part of the country is savanna and plains.35
Although most participants with podoconiosis wore 
footwear during the interview, many of them were 
wearing footwear that was not protective against exposure 
to soil. Additionally, many of those with lymphoedema 
reported that their use of footwear did not start until their 
early 20s, implying a substantial period of exposure to 
soil. Most podoconiosis cases reported living in a house 
with an earth or sand floor. This finding shows that key 
podoconiosis prevention practices (ie, consistent use of 
protective footwear from early age and covering floors in 
housing) are not widely practiced, even among individuals 
with the disease. Previous studies36 have shown that 
patients with podoconiosis tend to wear footwear more 
often than do the general population, often as a response 
to noticing foot swelling.
Our analysis is robust given the large sample size 
and widespread geographical coverage. However, a few 
limitations should be considered when interpreting the 
findings. First, the initial stage of house-to-house screening 
was done by community health workers who might have 
missed cases of early stage lymphoedema. However, the 
number of missed cases is probably minimal, given that 
30% of all cases identified were stage one when reviewed 
by trained clinicians. This value is higher than the 
proportion reported in either Ethiopia (16·7%)30 or 
Cameroon (9·6%).15 Additionally, previous studies37 have 
reported the high success rate of trained community 
health workers in identifying podoconiosis cases.
Second, we used a small number of datapoints in 
our analysis. As a result, we were unable to estimate 
small scale spatial variation in podoconiosis prevalence. 
Instead, we only used long-range variation, as modelled 
by precipitation, elevation, enhanced vegetation index, 
distance from closest waterway, clay content, silt content, 
night light emissivity, and distance to stable night 
light, which has also been the case in previous work.38 
None theless, we believe that our results provide a use-
ful operational framework for planning and setting 
priorities. For example, the exceedance probability map 
could be used to identify areas that need urgent inter-
vention (exceedance probability around 100%) and areas 
where additional sampling effort is required (exceedance 
probability around 50%).
Lastly, we did not include data on important determinant 
covariates, such as footwear use and foot hygiene practice. 
Such data were not available in the raster surface format, 
which is required for such analysis. Nonetheless, we used 
several proximal covariates to adjust for these. Future 
analysis should consider the use of these covariates as 
they become available.
Understanding the prevalence and number of cases of 
podoconiosis is crucial to informing policies and setting 
priorities. Our investigation showed that most tropical 
lymphoedema cases in Rwanda are due to podoconiosis. 
This finding implies that the Rwanda Ministry of Health 
should instigate a comprehensive podoconiosis response, 
including interventions targeted to increase footwear and 
foot hygiene practice for prevention of podoconiosis. 
For those with the disease, ensuring access to simple 
hygiene-based management is critical. This access can be 
achieved by training health workers at health centres 
and district hospitals to manage cases. With expanding 
services, efforts must focus on community-level 
awareness about podoconiosis and improved patient 
access to services. Integration of morbidity management 
within general health services has been feasible in 
Ethiopia. Integration not only ensures sustainability but 
also increases access to services for people affected 
within reasonable reach. Rwanda is well placed to 
integrate these services in the national health system 
through the support of community health workers and 
primary health-care services.28 Inclusion of podoconiosis 
interventions within national health insurance will 
provide better financial risk protection for affected 
individuals and families who do not have access to 
appropriate interventions.
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